Excessive leverage and risk in the financial system, e.g., using customer funds to speculate, never ends well. Stock market crashes, bank and investment firm failures or economic recessions are all potential consequences. Following the failure of the United States to regulate over the counter (OTC) derivatives...
Posted to
Hera
by
Ron Hera
on
Fri, Nov 16 2012
Filed under:
Filed under: Federal reserve, CPI, deflation, inflation, GDP, IMF, Great Depression, CDS, unemployment, debt monetization, too big to fail, International Monetary Fund, Gross Domestic Product, Consumer Price Index, MBS, mortgage backed securities, over the counter derivatives, European Central Bank, ECB, Baltic Dry Index, sovereign default, bank failure, credit default swaps, BDI, monetary policy, OMT, recession, stock market crash, liquidity, QE3, quantitative easing III, systemic collapse, outright monetary transactions, market intervention, stagflation, tax increases, austerity measures, savings, U.S. Treasury, bank credit, stagnation, economic opportunity, Federal Reserve Chairman Ben Bernanke, instability, entrepreneurship, public funds, jobs, financial crisis, operation twist, bond yields, living standards, financial repression, Carmen M. Reinhart, OTC derivatives. Glass-Steagall Act, interest rates, net loss, middle class, consumer incomes, innovation, economic recovery
Perhaps the greatest modern champion of central economic planning was the 20th century English economist John Maynard Keynes. Keynes, who was a political socialist and for a time a central banker, advocated the idea that the government should play a large, active role in the economy. Among the consequences...
Posted to
Hera
by
Ron Hera
on
Sun, Jul 1 2012
Filed under:
Filed under: Federal reserve, GDP, OTC derivatives, CFTC, SEC, Gross Domestic Product, Securities and Exchange Commission, Goldman Sachs, Morgan Stanley, collateralized debt obligations, Obamacare, Pfizer, Commodities and Futures Trading Commission, Keynesian economics, Wells Fargo, Food and Drug Administration, GlaxoSmithKline, Lockheed Martin, Bank of America, General Dynamics, MBS, federal government debt, Rahn curve, CDOs, mortgage backed securities, Leviathan, J.P. Morgan Chase, FDA, Monsanto, Archer Daniels Midland, Northrop Grumman, Raytheon, over the counter derivatives, John Maynard Keynes, Johnson & Johnson, Behemoth, Boeing, Citigroup, Ziz